Vitamin D and colon cancer

Area of Science:

• Endocrinology
• Oncology
• Molecular Biology

Background:

• Vitamin D deficiency is classically linked to bone health issues.
• Emerging evidence associates vitamin D deficiency with increased risk for various diseases, notably colorectal cancer.
• The active metabolite, 1α,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)), exerts broad regulatory functions.

Purpose of the Study:

• To review the role of vitamin D and its active metabolite in colorectal cancer.
• To explore the molecular mechanisms by which 1,25(OH)(2)D(3) may influence colon cancer.
• To assess the current evidence for vitamin D's protective effects against colon cancer in humans and animal models.

Main Methods:

• Review of epidemiological, experimental, and molecular studies on vitamin D and colorectal cancer.
• Analysis of the mechanisms of action of 1,25(OH)(2)D(3) on colon carcinoma cells.
• Evaluation of data from animal models of intestinal tumorigenesis.
• Assessment of available human molecular, genetic, and clinical data.

Main Results:

• 1,25(OH)(2)D(3) regulates gene expression, inducing differentiation, controlling detoxification, sensitizing cells to apoptosis, and inhibiting proliferation of colon cancer cells.
• Animal models show that 1,25(OH)(2)D(3) and its analogues reduce intestinal tumor formation.
• Human data are limited but suggest a protective role for vitamin D in colon cancer.

Conclusions:

• Vitamin D, specifically its active metabolite 1,25(OH)(2)D(3), demonstrates anti-cancer properties relevant to colorectal cancer.
• While evidence suggests a protective role, more large-scale human trials are needed to confirm vitamin D's efficacy in colon cancer prevention and therapy.